Immunotherapy in Lung Cancer
Raid Aljumaily, MD, Assistant Professor, Department of Medicine/Hematology-Oncology
Upon completion of this session, participants will improve their competence and performance by being able to: Review the mechanism of action of immune checkpoint inhibitors. Discuss phase I, II and III clinical trials that showed benefit of immune checkpoint inhibitors in lung cancer. Review potential side effects of immune checkpoint inhibitors.
Speaker Disclosures: Dr. Aljumaily has no relevant financial relationships or affiliations with commercial interests to disclose.
For further information contact:
271-6651 ext. 54374